The Health News United Kingdom April 26 2018

  • A new treatment for non-cancerous enlargement of the prostate, a very common condition in older men, has been recommended for use by the NHS. It’s called prostate artery embolisation or PAE. And it blocks some of the blood supply to the prostate using tiny synthetic beads, causing the troublesome tissue to shrink and die. Officials say there is good evidence that the non-invasive treatment works. And it can spare men surgery and side-effects, such as impotence.
  • Record numbers of nurses and midwives from EU27 countries quit Britain last year, fuelling fears that a Brexit brain drain will deepen the NHS’s already chronic staffing crisis. A total of 3,962 such staff from the European Economic Area (EEA) left the Nursing and Midwifery Council register between 2017-2018.
  • A treatment to prevent migraines could be on the horizon. A trial of a new monthly injection, called erenumab, found the drug can significantly reduce the frequency of migraines for regular sufferers and lessen their impact when they do strike. According to The Times, the injections could be available to migraine sufferers in the UK as early as next year.

News on Health Professional Radio. Today is the 26th of April 2018. Read by Tabetha Moreto.

http://www.bbc.com/news/health-43877002

A new treatment for non-cancerous enlargement of the prostate, a very common condition in older men, has been recommended for use by the NHS. It’s called prostate artery embolisation or PAE. And it blocks some of the blood supply to the prostate using tiny synthetic beads, causing the troublesome tissue to shrink and die. Officials say there is good evidence that the non-invasive treatment works. And it can spare men surgery and side-effects, such as impotence.

More than a third of men over the age of fifty have an enlarged prostate, which can make if difficult for them to pass urine. Drugs or an operation can help, but the National Institute for Health and Care Excellence says men should now be offered another treatment option. PAE can be done under local anaesthetic as a day case, meaning patients can go home shortly afterwards without having to be admitted to hospital, unlike conventional prostate surgery. Doctors pass a small tube into an artery in the groin that can be guided into the small blood vessels of the prostate. About twenty centres in the UK have already been offering the treatment as part of a trial.
….
The NICE advice is for England, but Scotland, Wales and Northern Ireland can choose to implement it too. In two thousand sixteen, NICE also recommended another prostate treatment – a laser therapy that can vaporise the overgrown tissue.

https://www.theguardian.com/society/2018/apr/25/brexit-blamed-record-number-eu-nurses-give-up-britain

Record numbers of nurses and midwives from European Union twenty seven countries quit Britain last year, fuelling fears that a Brexit brain drain will deepen the NHS’s already chronic staffing crisis. A total of three thousand nine hundred sixty two such staff from the European Economic Area or EEA left the Nursing and Midwifery Council register between two thousand seventeen and two thousand eighteen. The register tracks who is eligible to work in those areas of healthcare in the UK. The number of departures was twenty eight percent more than the three thousand eighty one who left in two thousand sixteen and two thousand seventeen and three times higher than the one thousand three hundred eleven who did so in two thousand thirteen and two thousand fourteen, the first year the NMC began keeping data on such departures.

At the same time, the number of EU nurses and midwives coming to work in the UK has fallen to its lowest level. Just eight hundred five of them joined the NMC register in two thousand seventeen and two thousand eighteen. That total is just thirteen percent of the six thousand three hundred eighty two who came over the year before.
….
Brexit emerged as a key reason why EU-trained staff are stopping working in the UK in interviews the NMC conducted with three thousand four hundred ninety six people who left the register between June and November two thousand seventeen. Almost half (forty seven percent) of the two hundred twenty seven EEA nurses and midwives who responded agreed that “Brexit has encouraged me to consider working outside the UK”, while fifty nine percent said: “I am leaving or have left the UK.”

https://www.huffingtonpost.co.uk/entry/monthly-injection-to-prevent-migraines-could-be-available-next-year_uk_5ad72187e4b03c426da9cd07?utm_hp_ref=uk-health-news

A migraine is more than just a headache, having potentially debilitating effects on the one in five women and one in fifteen men affected in the UK. But a treatment to prevent migraines could be on the horizon. A trial of a new monthly injection, called erenumab, found the drug can significantly reduce the frequency of migraines for regular sufferers and lessen their impact when they do strike.   

According to The Times, the injections could be available to migraine sufferers in the UK as early as next year.  The exact cause of migraines is still unknown but scientists believe the pain and sensitivity to light associated with the condition is linked to a chemical in the brain called calcitonin gene-related peptide, or CGRP. Erenumab works by blocking the CGRP receptor in the brain. For the study, two hundred forty six people who had regular migraines were given injections of either one hundred forty milligrams of erenumab or a placebo once a month for three months.

Of the participants, thirty nine percent had been treated unsuccessfully with two other medications, thirty eight percent with three medications and twenty three percent with four medications. On average, participants experienced an average of nine migraines a month and used an acute migraine drug to stop an attack five times a month. Researchers found that after three months, the people treated with erenumab were nearly three times more likely to have reduced their migraine days by fifty percent or more than those treated with placebo.

A total of thirty percent of the people treated with erenumab had half the number of headaches compared to fourteen percent on the placebo. Those treated with the drug also had a greater average reduction in the number of days they had headaches and the number of days they needed to take drugs to stop the migraines. The findings follow another promising trial which found erenumab was effective in reducing the impact of migraines.

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.